Streetbeat News

FBLG

FibroBiologics Inc

Industry

Research and Development in Biotechnology (except Nanobiotechnology)

Open

3.59

Mkt cap

131M

Volume

146K

High

3.74

P/E Ratio

-6.20

52-wk high

46.00

Low

3.41

Div yield

N/A

52-wk low

1.08

FibroBiologics has partnered with Southern Star Research to conduct a Phase 1/2 clinical trial in Australia for their product candidate CYWC628, aimed at treating diabetic foot ulcers.

Portfolio Pulse from Benzinga Newsdesk

September 19, 2024 | 1:33 pm

EF Hutton analyst Jason Kolbert has reiterated a Buy rating for FibroBiologics (NASDAQ:FBLG) and maintained a price target of $16.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2024 | 11:56 am

FibroBiologics shares are trading lower following the announcement of a new patent application for fibroblast cell-based technology aimed at generating 3D hemopoietic organoids.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 3:57 pm

FibroBiologics has filed a patent application for a new technology that generates three-dimensional organoids using fibroblast cell-based technology. This development could have significant implications for the biotech industry.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 1:33 pm

EF Hutton has initiated coverage on FibroBiologics with a Buy rating and set a price target of $16.

Portfolio Pulse from Benzinga Newsdesk

September 04, 2024 | 4:17 pm

In Monday's after-market session, several health care stocks experienced significant price movements. Conduit Pharmaceuticals, TNF Pharmaceuticals, and Holdco Nuvo Group DG were among the top gainers, while Renalytix, Bluejay Diagnostics, and IO Biotech saw notable declines.

Portfolio Pulse from Benzinga Insights

September 02, 2024 | 8:31 pm

FibroBiologics has filed a patent application for a new wound healing technology using an adhesive bandage with fibroblast cell-based technology. This innovation could enhance the company's product offerings and market position.

Portfolio Pulse from Benzinga Newsdesk

August 20, 2024 | 1:31 pm

FibroBiologics shares are trading lower following the release of their Q2 financial results.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 3:24 pm

FibroBiologics, Inc. (NASDAQ:FBLG) reported Q2 earnings of $0.03 per share, significantly beating the analyst consensus estimate of $(0.09) and showing a 137.5% increase over the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 6:40 am

FibroBiologics has announced preliminary proof-of-concept results for its novel artificial thymus organoid technology, which could have significant implications for regenerative medicine and immune system therapies.

Portfolio Pulse from Benzinga Newsdesk

June 25, 2024 | 1:32 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.